FIELD: medicine; experimental oncology.
SUBSTANCE: invention can be used to treat melanoma in vivo. Method involves parenteral administration of a pharmacological agent—a bifunctional NOS/PDK inhibitor based on 1-isobutanoyl-2-isopropylisothiourea dichloroacetate T1084, daily for at least 5 days. Dose for mouse is 70.7 mg/kg, the human dose extrapolated by interspecies correction, taking into account the body surface area, is 5.89 mg/kg.
EFFECT: use of the invention enables pronounced and stable suppression of melanoma growth without induction of toxic effects.
1 cl, 2 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TARGETED THERAPY OF MALIGNANT GROWTHS | 2018 |
|
RU2699558C2 |
| COMPLEX ANTI-TUMORAL PRODUCT | 2020 |
|
RU2751776C2 |
| METHOD OF PHARMACOLOGICAL PROTECTION FROM IONIZING RADIATION | 2017 |
|
RU2663465C1 |
| IMPROVED METHOD FOR OBTAINING RADIOPROTECTIVE AGENT 1-ISOBUTANOYL-2-ISOPROPYLISOTHIOUREA HYDROBROMIDE | 2023 |
|
RU2806650C1 |
| RADIOPROTECTIVE PHARMACOLOGICAL AGENT | 2020 |
|
RU2733883C2 |
| METHOD FOR SUPPRESSING THE GROWTH OF B16 MELANOMA IN LABORATORY ANIMALS | 2022 |
|
RU2784443C2 |
| METHOD FOR INCREASING THE EFFECTIVENESS OF IONIZING RADIATION ON MELANOMA | 2021 |
|
RU2774032C1 |
| METHOD OF INCREASING THE EFFICIENCY OF PROTON THERAPY ON MELANOMA STEM CELLS | 2022 |
|
RU2798733C2 |
| TUMOUR THERAPY AGENT | 2019 |
|
RU2726801C1 |
| USE OF GOLD POLYACRYLATE AS A HUMAN MELANOMA CELL GROWTH INHIBITOR | 2018 |
|
RU2708626C1 |
